BRIEF published on 12/30/2024 at 12:44, 1 year 8 months ago Arkema procède à des rachats d'actions fin décembre 2024 Rachat D'actions Réglementation Financière ARKEMA Conformité Avec Les Normes De L'UE Décembre 2024
PRESS RELEASE published on 12/30/2024 at 12:39, 1 year 8 months ago Inside Information / Other news releases Arkema discloses trading in own shares from 23-27 December 2024, following regulations. Buyback transactions details available on Arkema's website Trading Disclosure Own Shares Regulations Buyback Transactions ARKEMA
PRESS RELEASE published on 12/30/2024 at 12:39, 1 year 8 months ago Informations privilégiées / Autres communiqués Arkema déclare avoir réalisé des achats d'actions propres conformément à la réglementation entre le 23 et le 27 décembre 2024 Transactions Réglementation Achats D'actions ARKEMA 27 Décembre 2024
BRIEF published on 12/23/2024 at 15:00, 1 year 8 months ago Arkema réalise des transactions sur ses propres actions Actions Propres Rachat D'actions Marché XPAR Réglementation UE ARKEMA
BRIEF published on 12/23/2024 at 15:00, 1 year 8 months ago Arkema carries out transactions on its own shares Share Buyback Own Shares EU Regulation XPAR Market ARKEMA
PRESS RELEASE published on 12/23/2024 at 14:55, 1 year 8 months ago Informations privilégiées / Autres communiqués Arkema déclare avoir effectué des achats d'actions propres entre le 17 et le 20 décembre 2024 selon la réglementation en vigueur Transactions Réglementation Achats D'actions ARKEMA 17-20 Décembre 2024
BRIEF published on 12/16/2024 at 15:58, 1 year 8 months ago Amundi Asset Management franchit le seuil de 5% chez ARKEMA Franchissement De Seuil Amundi Asset Management FCPE ARKEMA Capital Et Droits De Vote
BRIEF published on 12/16/2024 at 15:58, 1 year 8 months ago Amundi Asset Management crosses the 5% threshold at ARKEMA Amundi Asset Management FCPE Threshold Crossing ARKEMA Capital And Voting Rights
PRESS RELEASE published on 12/16/2024 at 15:53, 1 year 8 months ago Franchissement de seuil Déclaration de franchissement de seuil par Amundi Asset Management pour le compte du FCPE Arkema Actionnariat France. Augmentation à 5,69% du capital d'ARKEMA Amundi Asset Management Déclaration De Franchissement De Seuil ARKEMA FCPE Arkema Actionnariat France 5,69%
BRIEF published on 12/10/2024 at 10:49, 1 year 9 months ago BlackRock réduit sa participation dans Arkema Franchissement De Seuil Bourse Participations BlackRock ARKEMA
Published on 09/11/2026 at 04:00, 7 hours 30 minutes ago Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 13 hours 5 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 20 hours 10 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 20 hours 30 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/11/2026 at 10:15, 1 hour 15 minutes ago TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050
Published on 09/11/2026 at 09:20, 2 hours 10 minutes ago Cantourage Expands Portfolio with New Cannabis Active Ingredients for Innovative Compounded Medicines
Published on 09/11/2026 at 09:05, 2 hours 24 minutes ago ROHM's New High Anti-surge Chip Resistors in "SDR01 Series" Achieve 0.33W Rated Power in 0402 Size
Published on 09/11/2026 at 09:00, 2 hours 30 minutes ago Homann Holzwerkstoffe publishes its 2026 half-year report
Published on 09/11/2026 at 07:00, 4 hours 30 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 4 hours 30 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 4 hours 30 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
